Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anca C. Mihailov"'
Autor:
Bozena Kukielka-Budny, Alina Turcu, Philippe Debourdeau, Sylvie Rottey, Alfredo Zurlo, Cristina-Marinela Oprean, Andrzej Kawecki, Ulrich Keilholz, B. Zurawski, Javier Lavernia, Anca C. Mihailov, Bruno Dietrich, Jérôme Fayette, Ilaria Imarisio, Andreas Dietz, Simona Mihutiu, Gunnar Folprecht, Michael Schenker, Philippe Schafhausen, Sebastian Ochenduszko
Publikováno v:
Journal of Clinical Oncology. 36:59-59
59 Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU (F), and the epidermal growth factor receptor (EGFR) blocking monoclonal antibody cetuximab. CetuGEX is a new monoclonal antibody sharing the identical EGFR-bindin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15c3651f50e1bafa31b39bdb8006d9b1
https://doi.org/10.1200/jco.2018.36.5_suppl.59
https://doi.org/10.1200/jco.2018.36.5_suppl.59
Autor:
Xavier Sagaert, Igor Kiss, Grahame Mark Jeffery, Evaristo Maiello, Zacharenia Saridaki, Valentina Pomella, Sandra Merino, Pratyaksha Wirapati, Peter Kerr, Meinolf Karthaus, Anca C. Mihailov, Joseph McKendrick, Razvan-Ovidiu D. Curca, Sabine Tejpar, Ben Vandenbosch, John Bridgewater
Publikováno v:
Journal of Clinical Oncology. 35:3538-3538
3538 Background: Addition of (ziv)-aflibercept (A) to FOLFIRI in second-line therapy for metastatic colorectal cancer (CRC) has been shown to be beneficial in phase III VELOUR trial (NCT00561470). A follow-up study (NCT01754272) was undertaken to acq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19011c3c51ade72fe359d3c548836f0e
https://doi.org/10.1200/jco.2017.35.15_suppl.3538
https://doi.org/10.1200/jco.2017.35.15_suppl.3538